⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021657 | 1.00 | — | — | |
| SCHEMBL22021684 | 1.00 | — | — | |
| SCHEMBL22021682 | 1.00 | — | — | |
| SCHEMBL22022270 | 0.98 | — | — | |
| SCHEMBL23639750 | 0.90 | NR1I2 (0.31) | — | |
| SCHEMBL22021693 | 0.89 | — | — | |
| SCHEMBL22166529 | 0.89 | — | — | |
| SCHEMBL23639746 | 0.88 | — | — | |
| SCHEMBL22022220 | 0.86 | — | — | |
| SCHEMBL22454227 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220220124-A1 | NOVEL COMPOUNDS HAVING BET, ESTROGEN RECEPTOR, AND ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-07-14 | — | — | US | disclosed |
| US-20210213012-A1 | COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER | ACCUTAR BIOTECHNOLOGY INC. | 2021-07-15 | — | — | US | disclosed |
| US-10696659-B2 | Compounds having estrogen receptor alpha degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2020-06-30 | — | — | US | disclosed |